

Company registration number 373122 (Republic of Ireland)

FIRHOUSE PHARMACY HOLDING LIMITED
ABRIDGED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 AUGUST 2025

FIRHOUSE PHARMACY HOLDING LIMITED

CONTENTS

| | Page |
|---------------------------------------|-------------|
| Directors' responsibilities statement | 1 |
| Statement of financial position | 2 - 3 |
| Notes to the financial statements | 4 - 7 |

FIRHOUSE PHARMACY HOLDING LIMITED

DIRECTORS' RESPONSIBILITIES STATEMENT

FOR THE YEAR ENDED 31 AUGUST 2025

The directors are responsible for preparing the Directors' Report and the financial statements in accordance with applicable Irish law and regulations.

Irish company law requires the directors to prepare financial statements for each financial year. Under that law, the directors have elected to prepare the financial statements in accordance with the Companies Act 2014 and FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (Generally accepted Accounting Practice in Ireland) issued by the Financial Reporting Council. Under company law, the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the assets, liabilities and financial position of the company as at the financial year end date and of the profit or loss of the company for that financial year and otherwise comply with the Companies Act 2014.

In preparing these financial statements, the directors are required to:

- select suitable accounting policies for the company financial statements and then apply them consistently;
- make judgements and estimates that are reasonable and prudent;
- state whether the financial statements have been prepared in accordance with applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for ensuring that the company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the company, enable at any time the assets, liabilities, financial position and profit or loss of the company to be determined with reasonable accuracy, enable them to ensure that the financial statements and Directors' Report comply with the Companies Act 2014. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

By order of the board



Donncha McDermott
Secretary



Fiona Marie McDermott
Director

28 November 2025

FIRHOUSE PHARMACY HOLDING LIMITED

STATEMENT OF FINANCIAL POSITION

AS AT 31 AUGUST 2025

| | | 2025 | | 2024 | |
|-------------------------------------------------------|-------|-------------|-------------|-------------|-------------|
| | Notes | € | € | € | € |
| Fixed assets | | | | | |
| Financial assets | 3 | | 4,538,844 | | 4,538,844 |
| Current assets | | | | | |
| Debtors | 4 | 25,000 | | 20,000 | |
| Cash at bank and in hand | | 5,184 | | 5,184 | |
| | | | 30,184 | | 25,184 |
| Creditors: amounts falling due within one year | 5 | (2,468,274) | | (2,457,224) | |
| Net current liabilities | | | (2,438,090) | | (2,432,040) |
| Net assets | | | 2,100,754 | | 2,106,804 |
| Capital and reserves | | | | | |
| Called up share capital presented as equity | 6 | | 11 | | 11 |
| Share premium account | | | 853,843 | | 853,843 |
| Capital redemption reserve | | | 17 | | 17 |
| Profit and loss reserves | | | 1,246,883 | | 1,252,933 |
| Total equity | | | 2,100,754 | | 2,106,804 |

FIRHOUSE PHARMACY HOLDING LIMITED

STATEMENT OF FINANCIAL POSITION (CONTINUED)

AS AT 31 AUGUST 2025

We, as directors of Firhouse Pharmacy Holding Limited, state that:

(a) The company is availing itself of the exemption from audit provided for by Chapter 15 of Part 6 of the Companies Act 2014.

(b) The company is availing itself of the exemption on the grounds that the conditions specified in section 359 are satisfied.

(c) The shareholders of the company have not served a notice on the company under section 334(1) in accordance with section 334(2).

(d) The directors acknowledge the obligations of the company, under the Companies Act 2014:

(i) to keep adequate accounting records and prepare financial statements which give a true and fair view of the assets, liabilities and financial position of the company at the end of its financial year and of its profit or loss for such a year; and

(ii) to otherwise comply with the provisions of this Act relating to financial statements so far as they are applicable to the company.

(e) The company has relied on the specified exemption contained in section 352 Companies Act 2014; the company has done so on the grounds that the company is entitled to the benefit of that exemption as a small company and the abridged financial statements have been properly prepared in accordance with section 353 Companies Act 2014.

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with Financial Reporting Standard 102 'The Financial Statement Reporting Standard applicable in the UK and Republic of Ireland'.

The financial statements were approved by the board of directors and authorised for issue on 28 November 2025 and are signed on its behalf by:



Fiona Marie McDermott
Director



Donncha McDermott
Director

FIRHOUSE PHARMACY HOLDING LIMITED

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 AUGUST 2025

1 Accounting policies

Company information

Firhouse Pharmacy Holding Limited is a limited company domiciled and incorporated in the Republic of Ireland. The registered office is Firhouse Shopping Mall, Ballycullen Avenue, Dublin 24 and its company registration number is 373122.

1.1 Basis of preparation

These financial statements have been prepared in accordance with FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" ("FRS 102"), as adapted by Section 1A of FRS 102, and the requirements of the Companies Act 2014.

The financial statements are prepared in euros, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest €.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2 Fixed asset investments

Interests in subsidiaries, associates and jointly controlled entities are initially measured at cost and subsequently measured at cost less any accumulated impairment losses. The investments are assessed for impairment at each reporting date and any impairment losses or reversals of impairment losses are recognised immediately in profit or loss.

A subsidiary is an entity controlled by the company. Control is the power to govern the financial and operating policies of the entity so as to obtain benefits from its activities.

1.3 Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.4 Financial instruments

The company has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the company's statement of financial position when the company becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

FIRHOUSE PHARMACY HOLDING LIMITED

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 AUGUST 2025

1 Accounting policies

(Continued)

Basic financial liabilities

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest.

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

1.5 Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

1.6 Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the income statement because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company's liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the income statement, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

1.7 Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

The cost of any unused holiday entitlement is recognised in the period in which the employee's services are received.

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

FIRHOUSE PHARMACY HOLDING LIMITED

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 AUGUST 2025

1 Accounting policies (Continued)

1.8 Foreign exchange

Transactions in currencies other than euros are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation in the period are included in profit or loss.

2 Employees

The average monthly number of persons (including directors) employed by the company during the year was:

| | 2025 Number | 2024 Number |
|-------|----------------|----------------|
| Total | 2 | 2 |

3 Financial assets

| | 2025 € | 2024 € |
|------------------------------|-----------|-----------|
| Shares in group undertakings | 4,538,844 | 4,538,844 |

4 Debtors

| | 2025 € | 2024 € |
|---------------------------------------------|-----------|-----------|
| Amounts falling due within one year: | | |
| Corporation tax recoverable | 5,000 | - |
| Other debtors | 20,000 | 20,000 |
| | 25,000 | 20,000 |

5 Creditors: amounts falling due within one year

| | 2025 € | 2024 € |
|------------------------------------|-----------|-----------|
| Amounts owed to group undertakings | 2,467,224 | 2,456,239 |
| Accruals | 1,050 | 985 |
| | 2,468,274 | 2,457,224 |

FIRHOUSE PHARMACY HOLDING LIMITED

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 AUGUST 2025

| | | | | | |
|----------|--------------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|
| 6 | Called up share capital | | | | |
| | | 2025 | 2024 | 2025 | 2024 |
| | Ordinary share capital | Number | Number | € | € |
| | Authorised equity | | | | |
| | Ordinary shares of 1c each | 99,999,840 | 99,999,840 | 999,998 | 999,998 |
| | | <u> </u> | <u> </u> | <u> </u> | <u> </u> |
| | Issued and fully paid | | | | |
| | Ordinary shares of 1c each | 1,116 | 1,116 | 11 | 11 |
| | | <u> </u> | <u> </u> | <u> </u> | <u> </u> |

7 Events after the reporting date

There are no significant post balance sheet events which require disclosure.

8 Related party transactions

The following related parties have been identified:

Dermot Moran (Firhouse) Limited - a company with common directors and shareholders
Firhouse Property Limited - a company with common directors and shareholders
Donncha McDermott, director and shareholder

Included in creditors is balance owing to Dermot Moran (Firhouse) Limited €2,447,224 (2024: €2,436,239 Cr).

Included in creditors is balance owing to Firhouse Property Limited €20,000 (2024: €20,000).

Included in debtors is balance owing from Donncha McDermott €20,000 (2024: €20,000).

9 Directors' and secretary's interests in shares

The directors' and secretary's interests in the shares of the company are as stated below:

| | Ordinary shares of 1c each | |
|-----------------------|-----------------------------------|-----------------------|
| | 1 September 2024 | 31 August 2025 |
| Fiona Marie McDermott | - | 372 |
| Donncha McDermott | 1,116 | 744 |

10 Approval of financial statements

The directors approved the financial statements on 28 November 2025.